Verona Gears Up for First Novel COPD Approval in Over a Decade

Patients with chronic obstructive pulmonary disease may soon have a new treatment option with fewer side effects as Verona Pharma prepares for a potential approval this week.

Wednesday, the FDA is set to decide on the New Drug Application for Verona’s ensifentrine, intended to treat chronic obstructive pulmonary disease (COPD), a condition in which patients have difficulty breathing due to restricted airflow to the lungs.